97176 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
Optimized fc variants and methods for their generation
#902Molecules with extended half-lives, compositions and uses thereof
#903DIAGNOSTIC AND THERAPEUTIC USES OF SOLUBLE FC-EPSILON RECEPTOR I FOR IGE-MEDIATED DISORDERS
#904FC RECEPTOR BINDING PROTEINS
#905Genetically modified human natural killer cell lines
#906Dye Conjugated Peptides for Fluorescent Imaging
#907Methods of making and using multispecific antibody panels and antibody analog panels
#908Glucagon/GLP-1 receptor co-agonists
#909Trispecific Therapeutics Against Acute Myeloid Leukaemia
#910Methods and compositions for inhibiting CD32B expressing cells
#911IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
#912COILED COIL AND/OR TETHER CONTAINING PROTEIN COMPLEXES AND USES THEREOF
#913Immunoconjugates
#914Identification and engineering of antibodies with variant Fc regions and methods of using same
#915SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb (FcgammaRIIb)
#916HUMANIZED FC GAMMA RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
#917Engineering Fc Antibody Regions to Confer Effector Function
#918Multivalent heteromultimer scaffold design and constructs
#919Optimized Fc variants and methods for their generation
#920Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in VIVO
#921Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
#922Engineered immunoglobulin FC polypeptides
#923Anti-CD19 antibodies
#924Screening of protein candidates
#925Methods and compositions for inhibiting CD32B expressing cells
#926Methods and compositions for inhibiting CD32B expressing cells
#927Methods and compositions for inhibiting CD32b expressing cells
#928FcγRIIB specific antibodies and methods of use thereof
#929Compositions and method for the diagnosis, prevention and treatment of alzheimer's disease
#930Compositions and methods for biological remodeling with frozen particle compositions
#931Compositions and methods for biological remodeling with frozen particle compositions
#932Dock-and-Lock (DNL) Complexes for Disease Therapy
#933Determination of Interactions of Constant Parts of Antibodies with FC-Gamma Receptors
#934Depletion of cancer stem cells
#935FcGammaRIIB Specific Antibodies and Methods of Use Thereof
#936Tetrameric cytokines with improved biological activity
#937Treatment of Fibrosis related disorders
#938Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
#939Molecules with extended half-lives, compositions and uses thereof
#940Identification and engineering of antibodies with variant FC regions and methods of using same
#941Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
#942Compositions and methods for the treatment of tumor of hematopoietic origin
#943Non-human mammals for the production of chimeric antibodies
#944MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
#945Antibodies Directed Against the Myelin Basic Protein Recognising an Epitope of CD64 and Their Use as Immunosuppressants
#946Method of using fusion proteins
#947Anti-FcRH5 antibodies and immunoconjugates and methods of use
#948CD16A Binding Proteins and Use for the Treatment of Immune Disorders
#949Frozen compositions and methods for piercing a substrate
#950Stably tethered structures of defined compositions with multiple functions or binding specificities
#951Dual Expression Vector System for Antibody Expression in Bacterial and Mammalian Cells
#952Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
#953METHOD FOR THE TREATMENT OR PROPHYLAXIS OF CHRONIC INFLAMMATORY DISEASES
#954FC RECEPTOR HOMOLOG ANTIBODIES AND USES THEREOF
#955Aglycosylated immunoglobulin mutants
#956Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
#957Anti-CD19 antibodies
#958FUSION OR LINKED PROTEINS WITH EXTENDED HALF LIFE
#959Monoclonal antibodies against CD32B
#960Use of bispecific antibodies to regulate immune responses
#961NON-GLYCOSYLATED RECOMBINANT MONOVALENT ANTIBODIES
#962Method for determining immune system affecting compounds
#963Humanized FcγRIIB-specific antibodies and methods of use thereof
#964Recombinant IgG4 monovalent antibodies
#965METHOD FOR EXTENDING THE HALF-LIFE OF EXOGENOUS OR ENDOGENOUS SOLUBLE MOLECULES
#966DIFFERENTIAL DIAGNOSIS OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
#967FcRN ANTIBODIES AND USES THEREOF
#968Anti-FcRH5 antibodies and immunoconjugates and methods of use
#969RECOMBINANT FUCOSE MODIFIED MONOVALENT HALF-ANTIBODIES OBTAINED BY MOLECULAR ENGINEERING
#970Immunoglobulin constant region FC receptor binding agents
#971CHAIN REACTION CREATING OLIGOMERS FROM REPEAT UNITS OF BINDING MOLECULES
#972Directed engagement of activating Fc receptors
#973Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
#974Treatment methods for fibrosis related disorders
#975FcgammaRIIB Fusion Proteins and Compositions Thereof
#976Engineering Fc antibody regions to confer effector function
#977Molecules with extended half-lives, compositions and uses thereof
#978Tetrameric cytokines with improved biological activity
#979SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS
#980Covalent diabodies and uses thereof
#981ORAL DELIVERY OF POLYPEPTIDES
#982Frozen compositions and methods for piercing a substrate
#983BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES
#984Frozen compositions and methods for piercing a substrate
#985Anti-FC-receptor single domain antibodies (nanobodies-tm) and therapeutic use
#986Frozen compositions and methods for piercing a substrate
#987Frozen compositions and array devices thereof
#988Compositions and methods for biological remodeling with frozen particle compositions
#989Frozen compositions and methods for piercing a substrate
#990Compositions and methods for biological remodeling with frozen particle compositions
#991Compositions and methods for biological remodeling with frozen particle compositions
#992Compositions and methods for biological remodeling with frozen particle compositions
#993Frozen piercing implements and methods for piercing a substrate
#994Frozen compositions and methods for piercing a substrate
#995Compositions and methods for biological remodeling with frozen particle compositions
#996Method of enhancing of binding activity of antibody composition to Fcγ receptor IIIa
#997Genetically modified human natural killer cell lines
#998Genetically modified human natural killer cell lines
#999Anti-CD19 antibodies
#1000Activation epitope of FcγRII (CD32), binding molecules that specifically bind the epitope and means and methods for the detection of the epitope, and uses of said epitope or said binding molecules
#1001Method for engineering immunoglobulins
#1002Fc receptor binding proteins
#1003Glyco-engineered antibodies
#1004Compositions and methods for drug delivery
#1005Recombinant monovalent antibodies and methods for production thereof
#1006Anti-CD16 binding molecules
#1007BINDING MEMBER TOWARDS PNEUMOLYSIN
#1008Optimized Fc Variants and Methods for Their Generation
#1009Production of antibody formats and immunological applications of said formats
#1010FcγRIIB specific antibodies and methods of use thereof
#1011Antibody-drug conjugates and methods
#1012Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
#1013Stably tethered structures of defined compositions with multiple functions or binding specificities
#1014Combination of FcγRIIB-specific antibodies and CD20-specific antibodies and methods of use thereof
#1015Optimized Fc Variants and Methods for Their Generation
#1016Methods and compositions for inhibiting CD32B expressing cells
#1017Methods of screening for compounds that inhibit binding between amyloid-β(Aβ) and FC-γ receptor IIB (FcγRIIb)
#1018Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors
#1019IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT HEAVY CHAINS AND METHODS OF USING SAME
#1020FcγRIIB specific antibodies and methods of use thereof
#1021Optimized Fc variants and methods for their generation
#1022Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
#1023Optimized Fc variants and methods for their generation
#1024FcγRIIB specific antibodies and methods of use thereof
#1025FcγRIIB specific antibodies and methods of use thereof
#1026Methods and compositions useful in the treatment of mucositis
#1027Optimized Fc variants and methods for their generation
#1028Optimized Fc variants and methods for their generation
#1029Covalent diabodies and uses thereof
#1030FcγRIIB specific antibodies and methods of use thereof
#1031FcγRIIB specific antibodies and methods of use thereof
#1032FcγRIIB specific antibodies and methods of use thereof
#1033FcGammaRIIB Specific Antibodies and Methods of Use Thereof
#1034Methods of diagnosing, treating, or preventing plasma cell disorders
#1035Optimized Fc Variants and Methods for Their Generation
#1036Irta-4 Antibodies and Their Uses
#1037GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
#1038Irta-2 Antibodies and Their Uses
#1039USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
#1040Bispecific molecules cross-linking ITIM and ITAM for therapy
#1041USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
#1042USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
#1043IRTA-5 ANTIBODIES AND THEIR USES
#1044Optimized Fc Variants and Methods for Their Generation
#1045USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
#1046Antibody-drug conjugates and methods
#1047ANTIBODY COMBINATION USEFUL FOR TUMOR THERAPY
#1048Identification and engineering of antibodies with variant Fc regions and methods of using same
#1049Identification and engineering of antibodies with variant Fc regions and methods of using same
#1050Fc Receptor Homolog Antibodies And Uses Thereof
#1051Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use
#1052Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
#1053Human monoclonal antibodies to Fc gamma receptor I (CD64)
#1054Members of the FC receptor homolog gene family (FcRH1-3,6) related reagents and uses thereof
#1055Monovalent ligand of the FcαRI receptor as an anti-inflammatory agent
#1056MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
#1057CD16A binding proteins and use for the treatment of immune disorders
#1058FcγRIIB—specific antibodies and methods of use thereof
#1059Humanized FcγRIIB-specific antibodies and methods of use thereof
#1060Substance binding human IgG Fc receptor IIb (FcγRIIb)
#1061Antibodies with altered effector functions
#1062Human monoclonal antibodies to FC gamma receptor II (CD32)
#1063Anti-FC-gamma RIIB receptor antibody and uses therefor
#1064CD16A binding proteins and use for the treatment of immune disorders
#1065OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
#1066CD20 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
#1067CD52 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
#1068Her2/neu OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
#1069Medicinal compositions containing Fc receptor γ chain activator
#1070Optimized Fc variants and methods for their generation
#1071Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
#1072Molecules with extended half-lives, compositions and uses thereof
#1073Anti-FcRn antibodies for treatment of auto/allo immune conditions
#1074Compositions and methods for suppressing fibrocytes
#1075Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
#1076Optimized Fc variants and methods for their generation
#1077Dual expression vector system for antibody expression in bacterial and mammalian cells
#1078Identification and engineering of antibodies with variant Fc regions and methods of using same
#1079Method of treating autoimmune disease using humanized anti-CD16A antibodies
#1080Compositions and methods for enhanced dendritic cell maturation and function
#1081Covalent diabodies and uses thereof
#1082Binding member towards pneumococcus surface adhesin a protein (psaa)
#1083Optimized Fc variants and methods for their generation
#1084Genetically modified human natural killer cell lines
#1085Use of CD23 Antagonists for the Treatment of Neoplastic Disorders
#1086Use of CD23 Antagonists for the Treatment of Neoplastic Disorders
#1087Ruminant mhc class-i-like fc receptors
#1088Bispecific antibody devoid of Fc region and method of treatment using same
#1089Stably tethered structures of defined compositions with multiple functions or binding specificities
#1090Compositions and methods for the treatment of tumor of hematopoietic origin
#1091Heteromultimeric molecules
#1092Molecules with extended half-lives, compositions and uses thereof
#1093Modulation of Fc gamma receptors for optimizing immunotherapy
#1094Method of promoting an immune response with a bispecific antibody
#1095FcgammaRIIB-specific antibodies and methods of use thereof
#1096USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
#1097Modulation of mesenchymal cells via iga-receptors
#1098Optimized Fc variants and methods for their generation
#1099Engineering Fc Antibody regions to confer effector function
#1100Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands
#1101Anti-Fc-gamma RIIB receptor antibody and uses therefor
#1102Humanized FcγRIIB-specific antibodies and methods of use thereof
#1103Method for determining a risk of atherosclerosis or future development of atherosclerotic complications
#1104Antibody-drug conjugates and methods
#1105Methods for producing and identifying multispecific antibodies
#1106Human anti-IRTA-5 antibodies
#1107Fcgamma-RIIB-specific antibodies and methods of use thereof
#1108Bispecific molecules for use in inducing antibody dependent effector cell-mediated cytotoxicity
#1109Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof
#1110Monovalent antibody fragments useful as therapeutics
#1111FcγRIIB specific antibodies and methods of use thereof
#1112Antibody combination useful for tumor therapy
#1113Medicinal compositions containing fc receptor gamma-chain activator
#1114Human type antihuman IgE receptor antibody and fragment
#1115Method for determining immune system affecting compounds
#1116Antibodies with altered effector functions
#1117Cells expressing anti-Fc receptor binding components
#1118Treatment of inflammatory conditions
#1119Compositions and methods for surrogate antibody modulation of an immune response and transport
#1120Bispecific anti-cd19x anti-cd16 antibodies and uses thereof
#1121Anti-FcRn antibodies for treatment of auto/allo immune conditions
#1122Optimized Fc variants
#1123Identification and engineering of antibodies with variant Fc regions and methods of using same
#1124Binding agents with differential activity
#1125Humanized mouse models of the FcRn recycling pathway